iSERA Lifesciences Ltd (534920)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 4 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 3 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
iSERA Lifesciences Ltd reported Q2 FY27 results on 4 Nov 2026: revenue ₹0.0 Cr, and net profit ₹-0.1 Cr (against a profit a year earlier).
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹0.0 | — | — |
| செயல்பாட்டு லாபம் | ₹-0.2 | — | நஷ்டம் குறைந்தது |
| நிகர லாபம் | ₹-0.1 | நஷ்டமாக | நஷ்டம் குறைந்தது |
| EPS (₹) | -0.62 | நஷ்டமாக | நஷ்டம் குறைந்தது |
- நஷ்டத்தில்: ஓராண்டுக்கு முன் லாபம்
- லாபம் இருந்தும் FY26-இல் செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
iSERA Lifesciences Limited received a warning letter from SEBI via email on November 6, 2026. The action was issued due to the company's failure to submit disclosures under Regulations 7(3), 13(3), and 47 of the SEBI Listing Regulations. The company reported that this development carries no financial, operational, or other quantifiable impact.
- SEBI issued a Warning Letter to the company received via email on 06.11.2026
- Non-compliances cited involve failure to submit filings under Regulations 7(3), 13(3), and 47
- Company confirmed no quantifiable monetary impact on financials or operations
iSERA Lifesciences Ltd (formerly Covidh Technologies Ltd) reported standalone financial results for the quarter ended September 30, 2026. The company posted nil revenue from operations, relying solely on other income of ₹7.88 lakh. Total expenses stood at ₹20.99 lakh, resulting in a net loss of ₹13.11 lakh for the quarter compared to a net loss of ₹33.62 lakh in the preceding quarter ended June 30, 2026. Cash and cash equivalents dropped sharply to ₹3.55 lakh from ₹286.62 lakh at the start of the year.
- Revenue from operations was ₹0.00 lakh for Q2 FY27 (quarter ended Sep 30, 2026), with total income of ₹7.88 lakh from other income.
- Net loss for the quarter stood at ₹13.11 lakh, an improvement from a loss of ₹33.62 lakh in Q1.
- Total expenses for the quarter were ₹20.99 lakh, mainly driven by administrative expenses of ₹16.09 lakh.
- Cash and cash equivalents fell to ₹3.55 lakh as of September 30, 2026, from ₹286.62 lakh at the beginning of the period.
- Basic and diluted EPS stood at negative ₹(0.62) for the quarter.
iSERA Lifesciences Limited has submitted continual disclosures under SEBI (PIT) Regulations reflecting equity share allotments executed on a share swap basis. Multiple promoters and allottees received equity shares, including Shubhangi Dhanraj Garad acquiring 27,55,000 shares (4.95%) and Sumeet Dhanraj Garad receiving 11,92,000 shares (4.06%). Other significant allotments include Dhairyasheel Vasantrao Yadav acquiring 4,50,500 shares valued at Rs 2.17 Cr, taking total holding to 15,65,500 shares (6.37%). The allotment date specified across filings was October 01, 2026.
- Shubhangi Dhanraj Garad acquired 27,55,000 equity shares (4.95% of paid-up capital) via share swap
- Sumeet Dhanraj Garad acquired 11,92,000 shares representing 4.06% of capital
- Dhairyasheel Vasantrao Yadav was allotted 4,50,500 shares worth Rs 2.17 Cr, increasing holding to 15,65,500 shares (6.37%)
- Babasaheb Mahadeo Bhosale acquired 80,000 shares valued at Rs 38.56 lakh
- Allotment of shares took place on October 01, 2026 pursuant to preferential allotment
Promoter Archana Kakasaheb Lonkar was allotted 4,95,000 equity shares in iSERA Lifesciences via preferential allotment (share swap) on October 1, 2026. Following this issuance, her absolute holding increased from 7,00,000 shares to 11,95,000 shares. However, due to a massive expansion in total share capital from 84,08,972 shares (Rs 8.41 Cr) to 2,45,91,772 shares (Rs 24.59 Cr), her percentage holding diluted from 8.32% to 4.86%.
- Promoter allotted 4,95,000 equity shares via preferential allotment under a share swap
- Absolute holding increased from 7,00,000 shares to 11,95,000 shares
- Percentage stake decreased from 8.32% to 4.86% due to total equity base expansion
- Total share capital expanded nearly threefold from 84,08,972 shares to 2,45,91,772 shares (Rs 24.59 Cr)
iSERA Lifesciences Limited has approved the allotment of 1,61,82,800 equity shares of face value Rs 10 each at an issue price of Rs 48.20 per share (including Rs 38.20 share premium). The total transaction value stands at approximately Rs 78 Cr, which dwarfs the company's TTM revenue of Rs 16 Cr and net worth of Rs 8 Cr. The allotment is executed via a 1:1 share swap with shareholders of iSERA Biological Limited. The issue covers 196 allottees spanning promoters, promoter groups, and marquee non-promoter individuals.
- Allotment of 1,61,82,800 fully paid-up equity shares approved on October 01, 2026
- Issued at Rs 48.20 per share (Rs 10 face value plus Rs 38.20 premium)
- Executed via a 1:1 share swap ratio for equity shares of iSERA Biological Limited
- Transaction covers 196 allottees including promoter and non-promoter categories
iSERA Lifesciences reported zero revenue from operations for the quarter ended June 30, 2026, a sharp decline from Rs 1.16 crore in the preceding quarter. The company posted a net loss of Rs 33.62 lakh, compared to a profit of Rs 54.98 lakh in Q4 FY26 and a loss of Rs 1.54 lakh in the same quarter last year. Total expenses for the quarter were Rs 33.62 lakh, almost entirely driven by 'Other Expenses' of Rs 31.31 lakh. The company's reserves remain negative at Rs -49.81 lakh, highlighting continued financial instability.
- Revenue from operations dropped to Rs 0 in Q1 FY27 from Rs 1.16 crore in the previous quarter.
- Net loss widened significantly to Rs 33.62 lakh from a loss of Rs 1.54 lakh in Q1 FY26.
- Other expenses accounted for 93% of total quarterly expenditure at Rs 31.31 lakh.
- Negative reserves increased to Rs -49.81 lakh as of June 30, 2026.
- Paid-up equity share capital remains constant at Rs 840.90 lakh.
iSERA Lifesciences Ltd has scheduled a board meeting for August 7, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026. The company currently operates with a TTM revenue of Rs 16 Cr and a net worth of Rs 0 Cr, resulting in a high debt-to-equity ratio of 22.17. Despite these fundamentals, the stock has seen an extreme 12-month price return of 4497.4%. The trading window for designated persons has been closed since July 1, 2026, in compliance with insider trading regulations.
- Board meeting scheduled for August 7, 2026, to approve Q1 FY27 results
- Trading window closure effective from July 1, 2026, until 48 hours post-results
- Company reports a TTM revenue of Rs 16 Cr against a debt of Rs 11 Cr
- Promoter holding recently stabilized at 58.63% in March 2026 after significant fluctuations
- Stock has delivered a 4497.4% return over the last 12 months
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
